GET DAILY SIGNALSRadiopharm Theranostics (RADX): Following Its Theranostic Pipeline in Oncology
Key Takeaways
- RADX is the Nasdaq-listed American Depositary Receipt (ADR) of Radiopharm Theranostics Limited, an Australian clinical-stage radiopharmaceuticals developer.
- The company develops "theranostic" radiopharmaceuticals that pair diagnostic imaging agents with targeted radiation therapies, primarily for oncology.
- Founded in 2021 and headquartered in Carlton, Victoria, Australia, the company has no approved products or meaningful product revenue and is funded largely through equity financings.
- Its pipeline targets brain metastases, breast, lung, pancreatic, and prostate cancers across both diagnostic and therapeutic programs.
- As a pre-revenue biotech, RADX carries elevated development, regulatory, and financing risk common to early-stage drug developers.
Company Background
Radiopharm Theranostics Limited (RADX) is a clinical-stage radiotherapeutics company focused on developing radiopharmaceutical products for diagnostic and therapeutic use in areas of high unmet medical need, primarily in oncology. Radiopharmaceuticals are medicines that combine a radioactive isotope with a targeting molecule, allowing radiation to be delivered selectively to diseased tissue. The company's "theranostics" approach — a fusion of "therapy" and "diagnostics" — aims to use the same or similar targeting platforms both to image a patient's disease and to treat it. Investors follow the company for its exposure to a growing niche within precision medicine, though it remains an early-stage, pre-revenue business. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Company Profile
Radiopharm Theranostics Limited was founded in 2021 by Paul A. Hopper and is headquartered in Carlton, Victoria, Australia. The company's ordinary shares trade on the Australian Securities Exchange (ASX), and its American Depositary Receipts — securities that represent ownership in a foreign company's shares and trade on U.S. exchanges — are listed on the Nasdaq Capital Market under the ticker RADX.
The company's business model centers on discovering, in-licensing, and advancing a portfolio of radiopharmaceutical drug candidates through preclinical and clinical development. Because it has no approved products, the company does not generate product revenue and relies primarily on equity financings to fund its research. Its long-term commercial strategy is to progress candidates toward regulatory approval and eventual commercialization or partnership, but it remains years away from potential product sales.
Pipeline and Technology
Radiopharm Theranostics' pipeline is organized around paired diagnostic and therapeutic candidates. Among its disclosed programs are:
- RAD101, a diagnostic candidate for brain metastases, and RAD102, its therapeutic counterpart.
- RAD201a and RAD202, nano-antibody (Nano-mAb) based programs targeting HER2-positive breast cancer.
- RAD203 and RAD204, Nano-mAb programs targeting PDL1 in non-small cell lung cancer.
- RAD301 and RAD302, programs aimed at pancreatic cancer via the Avß6-integrin target.
- RAD401 and RAD402, prostate-specific membrane antigen (PSA) targeted programs for prostate cancer.
This theranostic pairing is central to the company's strategy: a diagnostic agent can identify patients most likely to respond, while a matching therapeutic delivers targeted radiation to the same target. The company has reported early-stage clinical data across several of these programs, though none has reached approval. From what I see, this structure helps narrow down potential responders early in development.
Market Position and Competitive Landscape
Radiopharm Theranostics operates in the specialized radiopharmaceuticals segment of the broader biotechnology and precision-medicine market. The field has attracted growing attention as approved radiopharmaceuticals have demonstrated meaningful results in certain cancers, but it remains competitive, with participation from large pharmaceutical companies, specialized biotechs, and academic institutions. As a small, clinical-stage developer with a modest workforce and limited financial resources, Radiopharm Theranostics competes on the novelty of its targets and platform rather than on scale or commercial infrastructure. I’m watching this closely as the competitive dynamics evolve.
Why Investors Follow RADX
Investor interest in RADX is driven primarily by its exposure to the theranostics theme, which offers the potential for more personalized cancer treatment by linking imaging and therapy. The company's diversified pipeline across several solid-tumor types, combined with a platform-based approach that can be extended to additional targets, is a key part of its long-term value proposition. For investors, RADX represents a way to gain exposure to an emerging precision-oncology technology; however, its value is heavily tied to clinical trial outcomes and the company's ability to continue raising capital, rather than to established revenue or earnings.
Risks and Important Considerations
Several factors warrant careful consideration before investing in RADX. As a clinical-stage company, it faces substantial scientific and regulatory risk: drug candidates can fail in trials or be delayed by regulators. The company has no approved products and limited or no product revenue, meaning it must repeatedly secure financing — often through share issuances that can dilute existing holders — to sustain operations. Its small size, low trading volume relative to larger stocks, and reliance on a limited number of development programs also contribute to volatility and concentration risk. Finally, the broader radiopharmaceuticals field is subject to evolving reimbursement, manufacturing, and safety considerations that could affect commercial viability. One thing that stands out is how these risks are typical for the sector.
Using Tickeron’s AI Tools in Research
In my own analysis, Tickeron’s AI Screener has become a useful part of the process for reviewing stocks like RADX alongside peers. It allows filtering by technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable criteria to surface ideas that align with specific strategies. Whether focusing on momentum, value, or sector themes, the platform helps refine screening across thousands of stocks and ETFs. This supports a more structured approach to idea generation without replacing fundamental review.
Conclusion
Radiopharm Theranostics Limited stands out as a small, focused developer in the emerging field of theranostic radiopharmaceuticals, pairing diagnostic imaging with targeted radiation therapy across multiple oncology indications. Its pipeline breadth and platform approach give it a distinctive profile within precision medicine, but its pre-revenue status and reliance on ongoing capital raises make it a high-risk, early-stage investment proposition. For investors, RADX remains relevant as a pure-play exposure to a promising but unproven corner of cancer care, where clinical results — rather than current financial performance — will ultimately determine its trajectory.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for RADX turns negative, indicating new downward trend
RADX saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator turned negative. In 43 of the 46 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RADX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for RADX entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where RADX's RSI Oscillator exited the oversold zone, 8 of 8 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for RADX just turned positive on October 13, 2026. Looking at past instances where RADX's MACD turned positive, the stock continued to rise in 11 of 16 cases over the following month. The odds of a continued upward trend are 69%.
Following a +10.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where RADX advanced for three days, in 63 of 79 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
RADX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.263) is normal, around the industry mean (3.498). P/E Ratio (-0.051) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (8.681) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. RADX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RADX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement